Treatment of anaemia resistant to conventional erythropoietin therapy with thymopentin in haemodialysis patients

Meta‐analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end‐stage renal disease

“…TP5 is currently licensed for the treatment of immune dysfunctions related to impaired T‐cell activity. TP5 has been already used in ESRD patients as adjuvant to influenza vaccine 42 or in the treatment of uraemic anaemia resistant to conventional EPO therapy 43 . In a double‐blind study, thymopentin as adjuvant stimulated the antibody response to keyhole limpet hemocyanin antigen (KLH) vaccination in elderly volunteers 44 .…”